Special Issue

Advances in Cancer Therapeutics

Message from the Guest Editors

Cancer is the second leading cause of death worldwide, and drug therapy remains one of the most common and effective means of cancer treatment. Anti-cancer drug therapy includes chemotherapy, targeted therapy, anti-angiogenesis therapy, endocrine therapy, and immunotherapy. Cancer drug resistance is a common cause of cancer treatment failure, which is responsible for up to 90% of cancer-related deaths. In particular, the use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of cancer; some cancer patients could even have a complete response after ICI treatment. Thus, it is urgent to screen novel targets for appropriate use guidance, as well as to select appropriate drug combinations to combat drug resistance.   This Special Issue will focus on the optimization of cancer drug therapy through the exploration of biomarkers that could guide the use of anti-cancer drugs and help to identify the signaling pathways that participate in drug resistance as well as the drug combinations that are more effective in cancer treatment. Our ultimate goal is to achieve individualized treatment of cancer patients with precision medicine.

Guest Editors

Dr. Weidong Han

Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China

Dr. Yubin Zhou

Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (20 September 2024)

Cancers

mdpi.com/journal/
cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)